Energy Fuels is positioning itself as a key player in the nuclear energy sector with a diverse portfolio that includes uranium, rare earth elements, and medical isotopes.
Researchers from the University of Michigan and MD Anderson Cancer Center have developed a novel nanoparticle therapy that may enhance cancer immunotherapy's safety and efficacy.
Michigan's efforts in radiation emergency preparedness showcase a proactive approach that could serve as a model for health officials nationwide.
A suspected hantavirus outbreak on a Dutch cruise ship has led to the deaths of three passengers, raising alarms about health safety on cruises.
Recent developments suggest that a political appointee may be obstructing the approval process for a Sanofi drug, raising alarms about potential political interference at the FDA.
Sanofi has requested the FDA to withdraw teplizumab from its fast-track review program following internal disagreements regarding the drug's approval.
Following a surprising rejection, the FDA will revisit the treatment for a rare cancer, as the developers of Ebvallo have reached an agreement to tackle the concerns raised.
A recent report indicates a steady increase in hospital shootings since 2000, highlighting a troubling trend in healthcare safety and security.
In a significant move within the pharmaceutical industry, Angelini Pharma has announced its acquisition of Catalyst Pharmaceuticals, a company specializing in treatments for rare diseases, for $4.1 billion.
The commander of Fort Drum has called on state officials to back initiatives in nuclear energy and healthcare, highlighting the importance of these sectors.
The Trump administration's recent actions regarding drug policy appear inconsistent, as the White House endorses treatment methods while imposing new restrictions.
La Trobe scientists have made a pivotal discovery in the fight against dangerous drug-resistant bacteria.
As discussions around pharmaceutical pricing evolve, the 'Most Favored Nation' model emerges as a potential solution worth considering for its implications and benefits.
In a notable move, Sanofi has requested the FDA to withdraw its type 1 diabetes drug from the expedited review process, citing political interference as a key factor.
Color Health is broadening its services to include cancer care coordination, aiming to fill a significant void in the healthcare landscape.
The Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a substantial ad campaign aimed at the 340B drug discount program, highlighting its budget and focus.
KFF has unveiled an interactive dashboard that monitors public trust in health information sources and explores attitudes toward vaccines, reflecting current trends.
A recent KFF Health Tracking Poll indicates that MAHA voters are placing significant emphasis on reducing health care costs, overshadowing other health concerns.
The recent increase in gold mining activities in Brazil's Amazon raises serious environmental and health concerns, particularly regarding deforestation and mercury exposure.
A new tracker compiles details on federal and state litigation related to abortion restrictions, including the FDA's approval of Mifepristone and other regulations.